Release – GDEV announces results for the second quarter and first half of 2026

Posted on August 21, 2026August 21, 2026 by [email protected]

August 21, 2026 08:00 ET | Source: GDEV Inc.

LIMASSOL, Cyprus, Aug. 21, 2026 (GLOBE NEWSWIRE) — GDEV Inc. (NASDAQ: GDEV), an international gaming and entertainment company (“GDEV” or the “Company”) released its unaudited financial and operational results for the second quarter and first half-year ended June 30, 2026.

Second quarter 2026 financial highlights:

Revenue of $94 million decreased by 22% year-over-year.
Selling and marketing expenses of $33 million decreased by 38% year-over-year.
Profit for the period, net of tax, of $20 million in Q2 2026 increased vs. $17 million in Q2 2025.
Adjusted EBITDA amounted to $20 million in Q2 2026 decreased vs. $22 million in Q2 2025.

Second quarter and first half of 2026 financial performance in comparison

Second quarter 2026 financial performance

In the second quarter of 2026, our revenue decreased by $26 million (or 22%) year-over-year and amounted to $94 million. The decrease was primarily driven by a decrease in bookings.

Platform commissions decreased by $7 million (or 29%) in the second quarter of 2026 compared to the same period in 2025 in line with the decrease in revenue.

Game operation costs remained relatively stable at the level of $15 million in the second quarter of 2026 vs. $14 million in the second quarter of 2025.

Selling and marketing expenses in the second quarter of 2026 decreased by $20 million vs. the same period in 2025, amounting to $33 million. This decrease is driven by our continued focus on improving the efficiency of user acquisition activities. The decrease reflects a more selective approach to performance marketing, prioritizing channels that attract players with higher long-term value over broad-scale campaigns aimed at short-term growth.

General and administrative expenses remained stable at $9 million in the second quarters of both 2026 and 2025.

As a result of the factors above, together with (i) the effect of a net foreign exchange loss in the second quarter of 2026 in the amount of $1 million vs. a net foreign exchange gain in the amount of $1 million in the same period of the prior year and (ii) share of profits of equity accounted associates in the second quarter of 2026 in the amount of $2 million vs. the share of losses of equity accounted associates in the amount of $2 million in the same period of the prior year, we recorded a profit for the period, net of tax, of $20 million in the second quarter of 2026 compared with $17 million in the same period of 2025. Adjusted EBITDA in the second quarter of 2026 amounted to $20 million, a decrease of $2 million compared with the same period in 2025 driven primarily by the same factors as those affecting the profit, except for the share of profits or losses of equity accounted associates, which do not impact the Adjusted EBITDA.

Cash flows generated from operating activities were positive $10 million in the second quarter of 2026 compared with negative $10 million in the same period in 2025.

^{________________________}¹ For more information, see section titled “Presentation of Non-IFRS Financial Measures” on the last two pages of this report, including the reconciliation of the profit for the period, net of tax to the Adjusted EBITDA.

First half of 2026 financial performance

In the first half of 2026, our revenue decreased by $24 million (or 11%) year-over-year to $193 million. This decrease was primarily driven by a decrease in bookings.

Platform commissions decreased by $8 million (or 17%) in the first half of 2026 compared to the same period in 2025, driven by a decrease of revenues recognized from PC platforms.

Game operation cost remained stable at $28 million in the first halves of both 2026 and 2025.

Selling and marketing expenses in the first half of 2026 decreased by $25 million vs. the same period in 2025, amounting to $69 million. This decrease is driven by our continued focus on improving the efficiency of user acquisition activities. The decrease reflects a more selective approach to performance marketing, prioritizing channels that attract players with higher long-term value over broad-scale campaigns aimed at short-term growth.

General and administrative expenses remained relatively stable at $18 million in the first half of 2026 vs. $17 million in 2025.

As a result of the factors above, together with (i) the effect of a net foreign exchange loss in the first half of 2026 in the amount of $2 million vs. a net foreign exchange gain in the amount of $2 million in the same period of prior year and (ii) share of profits of equity accounted associates in the second quarter of 2026 in the amount of $2 million vs. the share of losses of equity accounted associates in the amount of $2 million in the same period of prior year, we recorded a profit for the period, net of tax, of $37 million compared with $31 million in the same period of 2025. Adjusted EBITDA in the first half of 2026 amounted to $39 million, an increase of $1 million compared with the same period in 2025 driven primarily by the same factors as those affecting the profit, except for the share of profits or losses of equity accounted associates, which do not impact the Adjusted EBITDA.

Cash flows generated from operating activities were positive $15 million in the first half of 2026 compared with negative $4 million in the same period in 2025.

Second quarter and first half 2026 operational performance comparison

Bookings declined in the second quarter and first half of 2026 to reach $73 million and $156 million, respectively, compared with $92 million and $173 million in the same periods in 2025. The decline was primarily due to a decline in monthly paying users of 23% and 15% in the second quarter and first half of 2026, respectively, vs. the same periods in 2025.

The share of advertisement sales as a percentage of total bookings decreased in the second quarter and first half of 2026 by 0.9 p.p. and 0.5 p.p. vs. the same period in 2025.

In the second quarter of 2026, the share of mobile and PC versions of our games remained relatively stable while in the first half of 2026 we recorded an increase in share of mobile to reach 64% vs. 61% in the same period in 2025 and a decrease in share of PC to reach 36% vs. 39% in the same period in 2025.

Our split of bookings by geography in the second quarter and first half of 2026 vs. the same periods in 2025 saw a decrease in the share of bookings derived from the US and Asia and an increase in bookings derived from other countries.

Note:

Due to rounding, the numbers presented throughout this release may not precisely add up to the totals. The period-over-period percentage changes are based on the actual numbers and may therefore differ from the percentage changes if those were to be calculated based on the rounded numbers.

Recent developments

On August 13, 2026, the Group entered into a game asset purchase agreement with an unrelated party for the sale of the mobile game “Island Hoppers”, together with all related intellectual property and game assets, for a total consideration of $5.0 million, of which $4.5 million was received upon execution and $0.5 million represents a deferred payment contingent on the satisfaction of a gross revenue condition and completion of the agreed migration obligations.

Island Hoppers contributed approximately 1% to the Group’s bookings in the first half of 2026 and approximately 3% in the year ended December 31, 2025.

As a result of the transaction, deferred revenue related to Island Hoppers’ bookings, totaling $2.1 million as of June 30, 2026, will be recognized on an accelerated basis, providing a one-time uplift to reported revenue in the period of closing.

About GDEV

GDEV is a gaming and entertainment holding company, focused on development and growth of its franchise portfolio across various genres and platforms. With a diverse range of subsidiaries including Nexters and Cubic Games, among others, GDEV strives to create games that will inspire and engage millions of players for years to come. Its franchises, such as Hero Wars, Island Hoppers, Pixel Gun 3D and others have accumulated over 550 million installs and $2.5 billion of bookings worldwide. For more information, please visit www.gdev.inc

Contacts:

Investor Relations
Roman Safiyulin | Chief Corporate Development Officer
[email protected]

Cautionary statement regarding forward-looking statements

Certain statements in this press release may constitute “forward-looking statements” for purposes of the federal securities laws. Such statements are based on current expectations that are subject to risks and uncertainties. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.

The forward-looking statements contained in this press release are based on the Company’s current expectations and beliefs concerning future developments and their potential effects on the Company. There can be no assurance that future developments affecting the Company will be those that the Company has anticipated. Forward-looking statements involve a number of risks, uncertainties (some of which are beyond the Company’s control) or other assumptions. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of the Company’s 2025 Annual Report on Form 20-F, filed by the Company on March 31, 2026, and other documents filed by the Company from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of the Company’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Presentation of Non-IFRS Financial Measures

In addition to the results provided in accordance with IFRS throughout this press release, the Company has provided the non-IFRS financial measure “Adjusted EBITDA” (the “Non-IFRS Financial Measure”). The Company defines Adjusted EBITDA as the profit/loss for the period, net of tax as presented in the Company’s financial statements in accordance with IFRS, adjusted to exclude (i) goodwill and investments in equity-accounted associates’ impairment, (ii) loss on disposal of subsidiaries, (iii) income tax expense, (iv) other financial income, finance income and expenses other than foreign exchange gains and losses and bank charges, (v) change in fair value of share warrant obligations and other financial instruments, (vi) share of loss of equity-accounted associates, (vii) depreciation and amortization, (viii) share-based payments expense and (ix) certain non-cash or other special items that we do not consider indicative of our ongoing operating performance. The Company uses this Non-IFRS Financial Measure for business planning purposes and in measuring its performance relative to that of its competitors. The Company believes that this Non-IFRS Financial Measure is a useful financial metric to assess its operating performance from period-to-period by excluding certain items that the Company believes are not representative of its core business. This Non-IFRS Financial Measure is not intended to replace, and should not be considered superior to, the presentation of the Company’s financial results in accordance with IFRS. The use of the Non-IFRS Financial Measure terms may differ from similar measures reported by other companies and may not be comparable to other similarly titled measures.

Reconciliation of the profit for the period, net of tax to the Adjusted EBITDA

Release – InPlay Oil Corp. Announces Closing of Highly Accretive Acquisition

Posted on August 21, 2026August 21, 2026 by [email protected]

Research News and Market Data on IPOOF

Aug 21, 2026, 09:17 ET

CALGARY, AB, Aug. 21, 2026 /CNW/ — InPlay Oil Corp. (TSX: IPO) (TASE: IPO) (OTCQX: IPOOF) (“InPlay” or the “Company“) is pleased to announce the closing of its previously announced acquisition of a private oil and gas producer for cash consideration of $54.25 million, prior to closing adjustments (the “Acquisition“). Further details regarding the Acquisition can be found in InPlay’s press release dated August 5, 2026.

The Acquisition adds approximately 1,400 boe/d⁽¹⁾(85% light oil and NGLs), bringing InPlay’s total Belly River production to approximately 2,000 boe/d and total corporate production to approximately 20,100 boe/d⁽¹⁾ (63% light oil and NGLs). InPlay has identified 50 drilling locations on the acquired assets including over 10 years of Tier 1 drilling inventory⁽²⁾. The Acquisition was completed at 2.0x net operating income⁽³⁾⁽⁴⁾ and delivered annualized per-share accretion of 18% to both Adjusted Funds Flow⁽⁵⁾ and Free Adjusted Funds Flow (“FAFF”)⁽³⁾, 12% to oil production per share, and 9% to funds flow per barrel netback.

ADVISORS

ATB Capital Markets acted as financial advisors to InPlay with respect to the Acquisition. Burnet, Duckworth & Palmer LLP acted as legal counsel to InPlay with respect to the Acquisition.

About InPlay Oil Corp.

InPlay Oil Corp. is a growth-oriented, sustainable oil and gas producer focused on long-term value creation for its shareholders. The Company’s operations are centered in the Western Canadian Sedimentary Basin, where InPlay holds a diverse portfolio of oil and natural gas assets. InPlay is committed to delivering strong per-share growth, maintaining a disciplined approach to capital investment, and providing consistent returns to shareholders.

For further information please contact:

Doug Bartole
President and Chief Executive Officer
InPlay Oil Corp.
Telephone: (587) 955-0632

Kevin Leonard
Vice President, Business & Corporate Development
InPlay Oil Corp.
Telephone: (587) 955-0635

Notes:
1.	See “Reader Advisories – Production Breakdown by Product Type” contained within this press release.
2.	See “Reader Advisories – Drilling Locations” for additional details.
3.	Non-GAAP financial measure or ratio. See “Reader Advisories – Non-GAAP and Other Financial Measures” for additional details.
4.	The acquired assets’ sustaining net operating income of $28 million multiplies 1,500 boe/d of sustaining production by the operating netback of $51.75/boe. Operating Netback estimate of $51.75/boe assumes current guidance commodity price assumptions of US$80.50 WTI, US$1.15 MSW differential, $1.75 AECO, 0.73 FX, in addition to $18.50/boe operating and transportation costs, and $16.90/boe royalties.
5.	Capital management measure. See “Non-GAAP and Other Financial Measures” for additional details.

Reader Advisories

Non-GAAP and Other Financial Measures

Throughout this document and other materials disclosed by the Company, InPlay uses certain measures to analyze financial performance, financial position and cash flow. These non-GAAP and other financial measures do not have any standardized meaning prescribed under GAAP and therefore may not be comparable to similar measures presented by other entities. The non-GAAP and other financial measures should not be considered alternatives to, or more meaningful than, financial measures that are determined in accordance with GAAP as indicators of the Company’s performance. Management believes that the presentation of these non-GAAP and other financial measures provides useful information to shareholders and investors in understanding and evaluating the Company’s ongoing operating performance, and the measures provide increased transparency and the ability to better analyze InPlay’s business performance against prior periods on a comparable basis.

Non-GAAP Financial Measures and Ratios

Included in this document are references to the terms “free adjusted funds flow”, “operating income” and “operating netback per boe”. Management believes these measures and ratios are helpful supplementary measures of financial and operating performance and provide users with similar, but potentially not comparable, information that is commonly used by other oil and natural gas companies. These terms do not have any standardized meaning prescribed by GAAP and should not be considered an alternative to, or more meaningful than “profit before taxes”, “profit and comprehensive income”, “adjusted funds flow”, “capital expenditures”, “net debt” or assets and liabilities as determined in accordance with GAAP as a measure of the Company’s performance and financial position.

Free Adjusted Funds Flow

Management considers FAFF an important measure to identify the Company’s ability to improve its financial condition through debt repayment and its ability to provide returns to shareholders. FAFF should not be considered as an alternative to or more meaningful than AFF as determined in accordance with GAAP as an indicator of the Company’s performance. FAFF is calculated by the Company as AFF less exploration and development capital expenditures and property dispositions (acquisitions) and is a measure of the cashflow remaining after capital expenditures before corporate acquisitions that can be used for additional capital activity, corporate acquisitions, repayment of debt or decommissioning expenditures or potentially return of capital to shareholders.

Operating Income/Operating Netback per boe/Operating Income Multiple

InPlay uses “operating income”, “operating netback per boe” and “operating income profit margin” as key performance indicators. Operating income is calculated by the Company as oil and natural gas sales less royalties, operating expenses and transportation expenses and is a measure of the profitability of operations before administrative, share-based compensation, financing and other non-cash items. Management considers operating income an important measure to evaluate its operational performance as it demonstrates its field level profitability. Operating income should not be considered as an alternative to or more meaningful than net income as determined in accordance with GAAP as an indicator of the Company’s performance. Operating netback per boe is calculated by the Company as operating income divided by average production for the respective period. Management considers operating netback per boe an important measure to evaluate its operational performance as it demonstrates its field level profitability per unit of production. Operating income multiple is calculated by the Company as the Acquisition consideration divided by operating income for the acquired assets for the relevant period. Management considers operating income multiple a key performance indicator as it is a key metric used to evaluate the Acquisition in comparison to other transactions. Refer below for a calculation of the operating income multiple in relation to the Acquisition.

		2026E
Net Consideration (before adjustments)	$ millions	$54.25
Operating Income	$ millions	$26.5
Operating Income Multiple		2.0x

Capital Management Measures

Adjusted Funds Flow

Management considers adjusted funds flow to be an important measure of InPlay’s ability to generate the funds necessary to finance capital expenditures. Adjusted funds flow is a GAAP measure and is disclosed in the notes to the Company’s financial statements for the three and six months ended June 30, 2026. All references to adjusted funds flow throughout this document are calculated as funds flow adjusting for foreign exchange loss, transaction and integration costs and decommissioning expenditures. Foreign exchange loss is primarily an unrealized movement on the Company’s NIS denominated Bonds due to movements in the CAD/NIS exchange rate. In addition, InPlay has effectively mitigated its exposure to fluctuations in the CAD to NIS exchange rate on the NIS denominated Bond by entering into NIS/CAD foreign exchange hedges with notional amounts and terms that align with the future cash outflow requirements of the Bonds. Therefore, at the end of the life of the Bonds, the FX impact on the Company will be insignificant. Transaction and integration costs are non-recurring costs for the purposes of an acquisition, making the exclusion of these items relevant in Management’s view to the reader in the evaluation of InPlay’s operating performance. Decommissioning expenditures are adjusted from funds flow as they are incurred on a discretionary and irregular basis and are primarily incurred on previous operating assets. The Company also presents adjusted funds flow per share whereby per share amounts are calculated using weighted average shares outstanding consistent with the calculation of profit per common share.

Production Breakdown by Product Type:

Disclosure of production on a per boe basis in this press release consists of the constituent product types as defined in National Instrument 51-101, Standards of Disclosure for Oil and Gas Activities (“NI 51-101“) and their respective quantities disclosed in the table below:

	Light and Medium Crude oil(bbls/d)	NGLs(boe/d)	Conventional Natural gas(Mcf/d)	Total(boe/d)
2025 Average Production	8,143	2,180	40,323	17,043
2026 Annual Guidance	9,605	2,290	43,530	19,150⁽¹⁾
Acquired Assets	1,125	92	1,100	1,400
Post-Acquisition	10,500	2,200	44,400	20,100

Notes:
1.	This reflects the mid-point of the Company’s 2026 production guidance range of 18,900 to 19,400 boe/d.
2.	With respect to forward‑looking production guidance, product type breakdown is based upon management’s expectations based on reasonable assumptions but are subject to variability based on actual well results.

BOE Equivalent

Barrel of oil equivalents or BOEs may be misleading, particularly if used in isolation. A BOE conversion ratio of 6 mcf: 1 bbl is based on an energy equivalency conversion method primarily applicable at the burner tip and does not represent a value equivalency at the wellhead. Given that the value ratio based on the current price of crude oil as compared to natural gas is significantly different than the energy equivalency of 6:1, utilizing a 6:1 conversion basis may be misleading as an indication of value.

Drilling Locations

This press release discloses drilling inventory in two categories: (a) proved locations; and (b) probable locations. Proved locations and probable locations are derived from the independent reserves evaluation effective December 31, 2025 for the acquired assets and account for drilling locations that have associated proved and/or probable reserves, as applicable. Of the 50 net drilling locations identified herein, 25.5 are proved locations and 1.8 are probable locations. The drilling locations considered for future development will ultimately depend upon the availability of capital, regulatory approvals, seasonal restrictions, oil and natural gas prices, costs, actual drilling results, additional reservoir information that is obtained and other factors.

Booked locations are proved locations and probable locations derived from the independent reserves evaluation effective December 31, 2025 for the acquired assets, respectively, and account for drilling locations that have associated proved and/or probable reserves, as applicable. We have not risked potential drilling locations, and actual locations drilled and quantities that may be ultimately recovered may differ substantially from estimates. We make no commitment to drill all of the drilling locations that have been identified. Factors affecting ultimate recovery include the scope of our on‐going drilling program, which will be directly affected by the availability of capital, drilling, and production costs, availability of drilling and completion services and equipment, drilling results, lease expirations, regulatory approvals, and geological and mechanical factors. Estimates of reserves, type/decline curves, EURs, per‐well economics, and resource potential may change significantly as development of our oil and gas assets provides additional data. Additionally, initial production rates are subject to decline over time and should not be reflective of sustained production levels.

Abbreviations

2026E	Estimate for the year ending December 31, 2026
AECO	Alberta Energy Company “C” Meter Station of the NOVA Pipeline System
bbl	barrel of oil
bbls	barrels of oil
boe	barrels of oil equivalent
boe/d	barrels of oil equivalent per day
GJ	gigajoules
IFRS	International Financial Reporting Standards
Mbbl	thousand barrels of oil
Mmbbl	million barrels of oil
Mboe	thousand boe
Mmboe	million boe
Mcf	thousand cubic feet
Mmcf	million cubic feet
MSW	Mixed sweet Alberta benchmark oil price
NGL	natural gas liquids
WTI	West Texas Intermediate benchmark Oil price

SOURCE InPlay Oil Corp.

Release – Star Equity Holdings, Inc. Declares Cash Dividend of $0.25 Per Share of 10% Series A Cumulative Perpetual Preferred Stock

Posted on August 21, 2026August 21, 2026 by [email protected]

Research News and Market Data on STRR

Aug 21, 2026

Download PDF

OLD GREENWICH, Conn., Aug. 21, 2026 (GLOBE NEWSWIRE) — Star Equity Holdings, Inc. (Nasdaq: STRR and STRRP) (“Star” or the “Company”), a diversified holding company, announced today announced today that its Board of Directors (the “Board”) declared a cash dividend to holders of the Company’s 10% Series A Cumulative Perpetual Preferred Stock of $0.25 per share. The record date for this dividend is September 1, 2026, and the payment date is September 10, 2026.

About Star Equity Holdings, Inc.
Star Equity Holdings, Inc. is a diversified holding company that seeks to build long-term shareholder value by acquiring, managing, and growing businesses with strong fundamentals and market opportunities. Its current structure comprises four divisions: Building Solutions, Business Services, Energy Services, and Investments. For more information visit www.starequity.com. On August 22, 2025, the Company completed its previously announced acquisition of Star Operating Companies, Inc. (“Star Operating”, formerly known as Star Equity Holdings, Inc.), pursuant to the Agreement and Plan of Merger, dated as of May 21, 2025 (the “Merger Agreement”), by and among the Company, Star Operating and HSON Merger Sub, Inc., a wholly owned subsidiary of the Company (“Merger Sub”). Upon the terms and subject to the conditions of the Merger Agreement, on August 22, 2025, at the effective time of the merger pursuant to the Merger Agreement (the “Merger”), Merger Sub merged with and into Star Operating, with Star Operating continuing as the surviving corporation of the Merger as a wholly owned subsidiary of the Company. Effective September 5, 2025, the Company changed (i) its name to Star Equity Holdings, Inc. and (ii) its trading symbol on Nasdaq to STRR and STRRP.

Building Solutions
The Building Solutions division operates in three niches: (i) modular building manufacturing; (ii) structural wall panel and wood foundation manufacturing, including building supply distribution operations; and (iii) glue-laminated timber (glulam) column, beam, and truss manufacturing.

Business Services
The Business Services division provides flexible and scalable recruitment solutions to a global clientele, servicing organizations at all levels, from entry-level positions to the C-suite. The division focuses on mid-market and enterprise organizations worldwide, partnering consultatively with talent acquisition, HR, and procurement leaders to build diverse, high-impact teams and drive business success.

Energy Services
The Energy Services division engages in the rental, sale, and repair of downhole tools used in the oil and gas, geothermal, mining, and water-well industries.

Investments
The Investments division manages and finances the Company’s real estate assets as well as its investment positions in private and public companies.

For more information contact:
The Equity Group
Lena Cati
Senior Vice President
212-836-9611
[email protected]

Forward-Looking Statements

This press release contains statements that the Company believes to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release, including statements regarding the Company’s future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “predict,” “believe,” and similar words, expressions, and variations of these words and expressions are intended to identify forward-looking statements. All forward-looking statements are subject to important factors, risks, uncertainties, and assumptions, including industry and economic conditions that could cause actual results to differ materially from those described in the forward-looking statements. Such factors, risks, uncertainties, and assumptions include, but are not limited to, (1) global economic fluctuations, (2) the Company’s ability to successfully achieve its strategic initiatives, (3) risks related to potential acquisitions or dispositions of businesses by the Company, (4) risks related to the market price of the Company’s common stock relative to the value paid pursuant to the Merger Agreement, (5) unexpected costs, charges or expenses resulting from the Merger, (6) potential adverse reactions or changes to business relationships resulting from the completion of the Merger, (7) risks related to the inability of the combined company to successfully operate as a combined business, (8) risks associated with the possible failure to realize certain anticipated benefits of the proposed Merger, including with respect to future financial and operating results, (9) risks related to fluctuations in the Company’s operating results from quarter to quarter due to various factors such as rising inflationary pressures and interest rates, (10) the loss of or material reduction in our business with any of the Company’s largest customers, (11) the ability of clients to terminate their relationship with the Company at any time, (12) competition in the Company’s markets, (13) the negative cash flows and operating losses that may recur in the future, (14) risks relating to how future credit facilities may affect or restrict our operating flexibility, (15) risks associated with the Company’s investment strategy, (16) risks related to international operations, including foreign currency fluctuations, political events, trade wars, natural disasters or health crises, including the Russia-Ukraine war, and potential conflict in the Middle East, (17) the Company’s dependence on key management personnel, (18) the Company’s ability to attract and retain highly skilled professionals, management, and advisors, (19) the Company’s ability to collect accounts receivable, (20) the Company’s ability to maintain costs at an acceptable level, (21) the Company’s heavy reliance on information systems and the impact of potentially losing or failing to develop technology, (22) risks related to providing uninterrupted service to clients, (23) the Company’s exposure to employment-related claims from clients, employers and regulatory authorities, current and former employees in connection with the Company’s business reorganization initiatives, and limits on related insurance coverage, (24) the Company’s ability to utilize net operating loss carryforwards, (25) volatility of the Company’s stock price, (26) the impact of government regulations and deregulation efforts, (27) restrictions imposed by blocking arrangements, (28) risks related to the use of new and evolving technologies, (29) the adverse impacts of cybersecurity threats and attacks, (30) risks associated with our real estate ownership, (31) risks associated with the costs and availability of supplies and materials due to trade tariffs or other factors affecting the commodities and materials we use in our business, (32) risks associated with liability claims and disputes, (33) risks associated with restrictions on our operations caused by our indebtedness, (34) risks associated with the shutdown of the U.S. federal government, (35) risks associated with changes in tax laws or relations, and (36) those risks set forth in “Risk Factors in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024.” The foregoing list should not be construed to be exhaustive. Actual results could differ materially from the forward-looking statements contained in this press release. In view of these uncertainties, you should not place undue reliance on any forward-looking statements, which are based on our current expectations. These forward-looking statements speak only as of the date of this press release. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Source: Star Equity Holdings, Inc.

Release – Lucky Strike Entertainment to Report Fourth Quarter and Full Year 2026 Financial Results on August 27, 2026

Posted on August 21, 2026August 21, 2026 by [email protected]

Research News and Market Data on LUCK

08/20/2026

RICHMOND, Va.–(BUSINESS WIRE)– Lucky Strike Entertainment (NYSE: LUCK), one of the world’s premier operators of location-based entertainment, will report financial results for the fourth quarter and full year fiscal 2026 on Thursday, August 27, 2026, before the U.S. stock market opens. Management will discuss the results via webcast at 9:00 AM ET on the same day.

The live webcast, replay, and results presentation will be available in the Events & Presentations section of the Lucky Strike Entertainment Investor Relations website at IR.LuckyStrikeEnt.com.

About Lucky Strike Entertainment

Lucky Strike Entertainment is one of the world’s premier location-based entertainment platforms. With over 360 locations across North America, Lucky Strike Entertainment provides experiential offerings in bowling, amusements, water parks, and family entertainment centers. The company also owns the Professional Bowlers Association, the major league of bowling and a growing media property that boasts millions of fans around the globe. For more information on Lucky Strike Entertainment, please visit IR.LuckyStrikeEnt.com.

[email protected]

Source: Lucky Strike Entertainment Corporation

View all news

Release – GeoVax Chairman and CEO David Dodd to Participate in 2026 Georgia Life Sciences Summit

Posted on August 20, 2026August 20, 2026 by [email protected]

Research News and Market Data on GOVX

Former Georgia Life Sciences Chair Selected for CEO Spotlight and Private Global Health Policy Roundtable With U.S. Rep. Rich McCormick

ATLANTA, Ga., August 20, 2026 — GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today announced that Chairman, President and Chief Executive Officer David Dodd will participate in two leadership and policy events associated with the 2026 Georgia Life Sciences Summit, August 25–26, at the Performing Arts Center in Sandy Springs, Georgia.

Dodd, a former Chair of Georgia Life Sciences, has been selected as one of four biotechnology CEOs participating in “CEO Spotlights: Decisions That Define a Company,” presented by BioSpark Labs, on August 26. The CEO Spotlights feature 10-minute, TED-style presentations focused on pivotal decisions, challenges and inflection points that have shaped the trajectory of each participating company.

Dodd will draw upon GeoVax’s evolution to discuss the leadership and strategic decisions involved in building and advancing a biotechnology company through changing scientific, financial, regulatory and public-health environments. The presentation will offer a candid perspective on navigating uncertainty, allocating resources, advancing innovative technologies and maintaining a long-term strategic vision while confronting the realities inherent in building a clinical-stage biotechnology company.

GeoVax today is advancing a diversified portfolio built around its Modified Vaccinia Ankara (MVA) vaccine platform and novel oncology technologies. Its programs include GEO-MVA, the Company’s vaccine candidate for mpox and smallpox; MVA-based vaccine candidates targeting Ebola, Sudan Ebola and Marburg viruses; and Gedeptin^®, a novel gene-directed therapy for solid tumors.

“Building a biotechnology company is rarely a straight line,” said Dodd. “It requires making consequential decisions with incomplete information, adapting to changing circumstances and remaining focused on the scientific and strategic opportunities that can ultimately create meaningful value. I look forward to sharing some of the decisions and lessons that have shaped GeoVax’s journey with Georgia’s life sciences community.”

Dodd will be joined in the CEO Spotlight program by Samir Patel, President and CEO of Moonlight Therapeutics; Dr. Nikhil L. Shah, CEO and Co-Founder of Nephrodite; and Gareth Sheridan, Founder and CEO of Nutriband.

Private Roundtable with Congressman Rich McCormick

On August 25, Dodd will also participate in a private roundtable discussion with U.S. Representative Rich McCormick (GA-07), convened by Georgia Life Sciences, the Global Health Technologies Coalition and The Kyle House Group.

The roundtable will bring together leaders from Georgia’s global health, biotechnology, nonprofit and private sectors to discuss the state’s leadership in advancing global health and development through innovation, research and public-private partnerships. Participants will also have the opportunity to discuss key policy priorities and issues before Congress directly with Congressman McCormick.

For GeoVax, the discussion provides an opportunity to contribute perspectives informed by the Company’s work in infectious disease vaccines, medical countermeasures and global health preparedness, as well as the challenges faced by emerging biotechnology companies working to translate scientific innovation into products addressing significant public-health needs.

“Georgia has developed an increasingly important life sciences and global health ecosystem that brings together scientific innovation, entrepreneurship, academic expertise, public policy and investment,” Dodd said. “Having previously served as Chair of Georgia Life Sciences, I am especially pleased to participate in this year’s Summit and to engage with Congressman McCormick and other leaders on how we can further strengthen Georgia’s – and America’s – capacity for biotechnology innovation, health security and global health leadership.”

The Georgia Life Sciences Summit is the organization’s flagship annual gathering, bringing together leaders from industry, academia, government and the investment community to address major issues affecting scientific research, product development, financing, business development and public policy while showcasing innovation across Georgia’s life sciences sector.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on the development of vaccines and immunotherapies addressing high-consequence infectious diseases and solid tumor cancers. GeoVax’s priority program is GEO-MVA, a Modified Vaccinia Ankara (MVA)–based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026, to address critical global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness. In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies, including planned neoadjuvant and first-line settings. GeoVax maintains a global intellectual property portfolio supporting its infectious disease and oncology programs and continues to evaluate strategic partnerships and funding opportunities aligned with its development priorities. For more information, visit www.geovax.com.

Forward-Looking Statements

This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.

Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Company Contact:

[email protected]

678-384-7220

Media Contact:

Jessica Starman

[email protected]

Release – Snail Games Unveils Gamescom 2026 Lineup Headlined by Upcoming AAA Title

Posted on August 20, 2026August 20, 2026 by [email protected]

Research News and Market Data on SNAL

August 20, 2026 at 2:05 PM EDT

PDF Version

CULVER CITY, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) — Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading independent global developer and publisher of interactive digital entertainment, unveils its Gamescom 2026 lineup that includes developing AAA titles, upcoming releases, and content updates across existing titles.

Taking the spotlight at Gamescom 2026 is the 9 Yin Sutra universe. Following the recent ChinaJoy announcement of 9 Yin Sutra: Immortal, Snail Games CEO, Hai Shi, will officially unveil another internally developed AAA title, expanding the franchise into a parallel timeline and alternate universe. Both titles are rooted in the acclaimed Age of Wushu IP, offering distinct takes on the martial arts world while building on one of Snail Games’ most established franchises. Alongside the upcoming 9 Yin Sutra titles, Snail Games will also showcase For The Stars, the Company’s other developing AAA title and ambitious space survival experience.

Meanwhile, Honeycomb: The World Beyond is gearing up for its recently announced September 8, 2026 launch. The upcoming survival adventure will be featured at Gamescom, giving attendees an early look at the game ahead of release. Players can also get an early, hands-on experience through a PC-exclusive preview demo expected to launch on August 31, 2026.

Bellwright will celebrate its community of over 1 million players while teasing an upcoming update with one of its most anticipated developments. Consistently the #1 player-requested feature, Bellwright’s latest feature represents a major step in how players will experience and move through the world. The Gamescom showcase will offer an early look at what’s coming while celebrating the community that has helped shape Bellwright.

Leading into Gamescom, Echoes of Elysium has received a new weather-focused tempest that makes rain a more meaningful part of gameplay. Rain now directly affects ships and their contents, with wet components and stored items gaining weight and drag. Certain stations can become inoperable when soaked, while the updated weather system brings a darker, more atmospheric feel to the world.

Visit the Snail Games Booth at Gamescom Hall 8.1 A-041

For Media interested in interviews at Gamescom please reach out to [email protected]

For Creators interested in collaborations please reach out to [email protected]

About Snail, Inc.
Snail, Inc. (Nasdaq: SNAL) is a leading global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs, and mobile devices. For more information, please visit: https://snail.com/.

Forward-Looking Statements
This press release contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this press release can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “may,” “predict,” “continue,” “estimate” and “potential,” or the negative of these terms or other similar expressions. Forward-looking statements appear in a number of places in this press release and include, but are not limited to, statements regarding Honeycomb: The World Beyond gearing up for its recently announced September 8, 2026 launch; the survival adventure being featured at Gamescom, players getting an early hands-on experience through a PC-exclusive preview demo launching August 31; Bellwright teasing one of its most anticipated developments: traversal at Gamescom: Snail Games USA showcasing For The Stars and the 9 Yin Sutra universe; and Snail Games USA’s CEO officially unveiling another new 9 Yin Sutra title at Gamescom, 9 Yin Sutra, expanding the franchise into a parallel timeline and alternate universe. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, the ability to launch The World Beyond on September 8, 2026 , the PC-exclusive demo and the other new games and titles when anticipated; acceptance of the Company’s titles in the marketplace and the successful development, marketing or sale of our titles and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2025, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.

Investor Contact:
John Yi and Steven Shinmachi
Gateway Group, Inc.
949-574-3860
[email protected]

Release – Conduent Collaborates with Google Cloud to Expand Enterprise AI Strategy and Deliver GenAI-Powered eDiscovery Solution

Posted on August 20, 2026August 20, 2026 by [email protected]

Research news and Market Data on CNDT

New GenAI capabilities for Legal Compliance & Analytics help legal teams accelerate review, reduce costs and improve defensibility at scale

August 20, 2026

Legal and Compliance Solutions Commercial Sector

Conduent Incorporated (Nasdaq: CNDT), a global technology-driven business solutions and services company, today announced it is expanding its enterprise AI strategy by collaborating with Google Cloud and integrating Google’s Gemini models into Conduent’s Viewpoint™ platform. The collaboration represents another milestone in Conduent’s strategy to embed GenAI across its technology platforms, helping clients modernize complex, essential workflows while improving speed, quality and operational efficiency.

Corporate legal departments are under increasing pressure to review growing volumes of structured and unstructured information while controlling costs, reducing risk and meeting tighter deadlines. By combining Conduent’s decades of legal operations expertise with Google Cloud’s AI technologies, organizations can analyze complex datasets faster, improve decision-making and deliver more defensible outcomes across eDiscovery and data breach response.

“Enterprise AI is not about replacing expertise, it is about amplifying it,” said George Wehbe, President, Commercial Solutions, Conduent. “Legal professionals are being asked to review exponentially more information with the same resources. By combining Conduent’s legal operations expertise with Google Cloud’s AI capabilities, we’re helping clients make faster, better-informed decisions while maintaining the governance, transparency and defensibility these matters demand.”

Driving Faster, Smarter Legal Outcomes
At the core of the collaboration is Enhanced Review, a GenAI-powered capability within Viewpoint, which applies user-defined protocols to identify relevant content, detect legal issues, and surface high-risk documents early in the review process.

Enabled by Google’s Gemini models, Enhanced Review delivers consistent, explainable results with transparent reasoning that helps legal teams understand not just what was identified, but why.

By embedding GenAI, Enhanced Review enables:

Faster insights — key case questions answered in minutes, not days
Lower costs — 30–60% reduction in document-intensive analysis effort
Reduced risk — improved accuracy, auditability, and defensibility

Extending AI Across the Legal Workflow
Beyond document review, Conduent’s collaboration with Google Cloud helps extend GenAI across the broader legal lifecycle. Viewpoint Apps use AI-powered analysis to convert large volumes of unstructured documents into structured, review-ready outputs, including chronologies, privilege logs and case reports, to accelerate insight while reducing manual effort.

In addition, Conduent’s CyberMine®, integrated with Viewpoint Data Breach Analyzer, automates breach response workflows by extracting participant data at scale, often spanning millions of records, deduplicating entries, and generating audit-ready notification lists, significantly reducing both response time and operational burden.

Built for Scale, Security, and Choice
Unlike cloud-only platforms, Viewpoint gives organizations full control over how and where their data is managed. Clients can deploy the full solution as SaaS on Google Cloud, on-premises or through managed services, ensuring alignment with regulatory, security and operational requirements. This flexibility, combined with Google Cloud’s global, high-performance infrastructure, enables organizations to scale eDiscovery operations without compromising data sovereignty or control.

Advancing Innovation in Legal and Compliance
Conduent’s collaboration with Google Cloud reflects a commitment to co-innovation and expanding the role of AI across legal and compliance workflows. Current capabilities focus on eDiscovery and data breach response, with planned expansion into areas such as contract analytics and investigations.

About Conduent
Conduent delivers digital business solutions and services spanning the commercial, government and transportation spectrum – creating valuable outcomes for its clients and the millions of people who count on them. The Company leverages cloud computing, artificial intelligence, machine learning, automation and advanced analytics to deliver mission-critical solutions. Through a dedicated global team of approximately 48,000 associates, process expertise and advanced technologies, Conduent’s solutions and services digitally transform its clients’ operations to enhance customer experiences, improve performance, increase efficiencies and reduce costs. Conduent adds momentum to its clients’ missions in many ways including disbursing approximately $80 billion in government payments annually, enabling approximately 2.0 billion customer service interactions annually, empowering millions of employees through HR services every year and processing over 14 million tolling transactions every day. Learn more at www.conduent.com .

Note: To receive RSS news feeds, visit www.news.conduent.com . For open commentary, industry perspectives and views, visit https://x.com/Conduent , http://www.linkedin.com/company/Conduent or http://www.facebook.com/Conduent .

Trademarks
Conduent is a trademark of Conduent Incorporated in the United States and/or other countries. Other names may be trademarks of their respective owners.

Media Contacts

Remy Kaul

Conduent

[email protected]

Release – Lands’ End Announces Second Quarter Fiscal 2026 Earnings Conference Call

Posted on August 20, 2026August 20, 2026 by [email protected]

Research News and Market Data on LE

DODGEVILLE, Wis., Aug. 20, 2026 (GLOBE NEWSWIRE) — Lands’ End, Inc. (NASDAQ: LE) will host a conference call at 8:30 a.m. Eastern Time on Thursday, September 3, 2026, to discuss its second quarter fiscal 2026 financial results.

A news release will be issued before the call and also be available on the Company’s investor relations website. Listeners may access a live broadcast of the conference call on the Company’s investor relations website: https://investors.landsend.com/ in the Events and Presentations section. An online archive of the broadcast will be available at approximately noon on September 3, 2026.

About Lands’ End, Inc.

Lands’ End, Inc. (NASDAQ: LE) is a leading digital retailer of solution-based apparel, swimwear, outerwear, accessories, footwear, home products and uniforms. Lands’ End offers products online at www.landsend.com, through third-party distribution channels and Company Operated stores. Lands’ End also offers products to businesses and schools, for their employees and students, through the Outfitters distribution channel. Lands’ End is a classic American lifestyle brand that creates solutions for life’s every journey.

CONTACTS:

Lands’ End, Inc.
Bernard McCracken
Chief Financial Officer
(608) 935-4100

Investor Relations:
ICR, Inc.
Tom Filandro
(646) 277-1235
[email protected]

Release – Kratos Receives Multi-Million-Dollar Orders for GAIA 100 Tri-Band Ground Station Systems Through Newly Acquired Orbit

Posted on August 19, 2026August 19, 2026 by [email protected]

Research News and Market Data on KTOS

August 19, 2026

PDF VersionOrders for both the GAIA 100 5.5-meter and the 6.1-meter systems underscore growing demand for Orbit’s GAIA tri-band S/X/Ka capability with advanced Ka-band tracking systems

SAN DIEGO, Aug. 19, 2026 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc., (NASDAQ: KTOS), a technology company in the defense, national security and global markets, today announced that Orbit Communication Systems Ltd. has received multi-million-dollar orders from multiple international customers for its GAIA 100 Tri-Band 5.5-meter and 6.1-meter antenna systems.

The orders, which support Earth Observation (EO), New Space and satellite communications applications, reflect continued demand for Orbit’s high-performance ground station solutions.

Alongside the announcement, Orbit is revealing the GAIA 100 Tri-Band 6.1, designed to deliver higher gain, improved link margins and enhanced Ka-band tracking performance. Supporting Earth Observation, New Space, defense and satellite communications applications, it combines advanced multi-band capability with a cost-effective, maintenance-free architecture.

“The market is placing increasing emphasis on ground station performance, particularly as satellite operators move toward higher-frequency communications and larger data volumes,” said Daniel Eshchar, General Manager of Orbit Communications Systems. “The GAIA 100 Tri-Band 6.1 was developed to address these evolving requirements by combining enhanced antenna performance, highly accurate Ka-band tracking and a robust, low-maintenance architecture within a single platform.”

The GAIA 100 Tri-Band 6.1 incorporates Orbit’s Auto Track technology, providing the pointing accuracy required for Ka-band communications. By combining integrated RF tracking with Orbit’s control architecture, the system maintains precise satellite alignment throughout the pass, maximizing link performance under demanding operating conditions.

The system’s integrated Radome architecture and robust mechanical design support long-term operation with minimal maintenance. By protecting critical antenna components from environmental exposure, the Radome increases system availability, extends service life and reduces lifecycle costs.

The 6.1-meter GAIA system builds on the proven capabilities of the GAIA family, including uninterrupted horizon-to-horizon tracking, full hemispherical coverage and support for LEO, MEO and GEO missions. Available in multiple antenna sizes and frequency configurations, the GAIA family enables operators to tailor systems to mission requirements while maintaining a common platform architecture.

Acquired by Kratos in March 2026, Orbit significantly expands Kratos’ microwave and digital systems portfolio by adding industry-leading satellite communications (SATCOM), tracking, and communications management technologies for airborne, maritime, land, and space applications. Combined with Kratos’ existing expertise in high-performance RF, microwave, and digital subsystem design and manufacturing, the acquisition strengthens the company’s ability to deliver increasingly integrated, end-to-end communications and mission solutions for defense, national security, and space customers. The combined capabilities position Kratos to address growing global demand for resilient, mission-critical connectivity supporting unmanned systems, satellite communications, electronic warfare, and multi-domain operations while accelerating innovation across rapidly expanding defense and space markets.

About Kratos Defense & Security Solutions
Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, system and software company addressing the defense, national security, and commercial markets. Kratos makes true internally funded research, development, capital and other investments, to rapidly develop, produce and field solutions that address our customers’ mission critical needs and requirements. At Kratos, affordability is a technology, and we seek to utilize proven, leading-edge approaches and technology, not unproven bleeding edge approaches or technology, with Kratos’ approach designed to reduce cost, schedule and risk, enabling us to be first to market with cost effective solutions. We believe that Kratos is known as an innovative disruptive change agent in the industry, a company that is an expert in designing products and systems up front for successful rapid, large quantity, low-cost future manufacturing which is a value-add competitive differentiator for our large traditional prime system integrator partners and also to our government and commercial customers. Kratos intends to pursue program and contract opportunities as the prime or lead contractor when we believe that our probability of win (PWin) is high and any investment required by Kratos is within our capital resource comfort level. We intend to partner and team with a large, traditional system integrator when our assessment of PWin is greater or required investment is beyond Kratos’ comfort level. Kratos’ primary business areas include virtualized ground systems for satellites and space vehicles including software for command & control (C2) and telemetry, tracking and control (TT&C), jet powered unmanned aerial drone systems, hypersonic vehicles and rocket systems, propulsion systems for drones, missiles, loitering munitions, supersonic systems, space craft and launch systems, C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter UAS, directed energy, communication and other systems, and virtual & augmented reality training systems for the warfighter. For more information, visit www.KratosDefense.com and follow Kratos on LinkedIn and X.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 28, 2025, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Press Contact:
Claire Cantrell
[email protected]

Kratos Investor Information:
877-934-4687
[email protected]

Release – 1-800-FLOWERS.COM, Inc. to Release its Fiscal 2026 Fourth Quarter and Year-End Results on Thursday, September 10, 2026

Posted on August 19, 2026August 19, 2026 by [email protected]

Research News and Market Data on FLWS

Aug 19, 2026

JERICHO, N.Y.–(BUSINESS WIRE)– 1-800-FLOWERS.COM, Inc. (NASDAQ: FLWS) (the “Company”),a leading provider of thoughtful expressions designed to help inspire customers to give more, connect more, and build more and better relationships, today announced that the Company will release financial results for its fiscal 2026 fourth quarter and year-end on Thursday, September 10, 2026. The press release will be issued before the market opens and will be followed by a conference call with members of senior management at 8:00 a.m. (ET).

The conference call will be available via live webcast on the Investors section of the Company’s website at www.1800flowersinc.com/investors. A replay of the webcast will be available shortly after the live event has concluded. A telephone replay of the call will be available beginning at 2:00 p.m. (ET) on September 10, 2026, through September 17, 2026, by dialing (855) 669-9658 or (412) 317-0088 for international callers; the passcode is 8022292.

Special Note Regarding Forward-Looking Statements:

Some of the statements contained in the Company’s press release and conference call regarding its fiscal 2026 fourth quarter and year-end results, other than statements of historical fact, may be forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the applicable statements. For a more detailed description of these and other risk factors, please refer to the Company’s SEC filings including its Annual Reports and Forms 10-K and 10-Q available at the Investor Relations section of the Company’s website at 1800flowersinc.com. The Company expressly disclaims any intent or obligation to update any of the forward-looking statements made in the scheduled conference call and any recordings thereof, or in any of its SEC filings, except as may be otherwise stated by the Company.

About 1-800-FLOWERS.COM, Inc.

1-800-FLOWERS.COM, Inc. is a leading provider of thoughtful expressions designed to help inspire customers to share more, connect more, and build more and better relationships. The Company’s e-commerce business platform features an all-star family of brands, including: 1-800-Flowers.com®, 1-800-Baskets.com®, Card Isle®, Cheryl’s Cookies®, Harry & David®, PersonalizationMall.com®, Shari’s Berries®, FruitBouquets.com®, Things Remembered®, Moose Munch®, The Popcorn Factory®, Wolferman’s Bakery®, Vital Choice®, Simply Chocolate® and Scharffen Berger®. Through the Celebrations Passport® loyalty program, which provides members with free standard shipping and no service charge on eligible products across our portfolio of brands, 1-800-FLOWERS.COM, Inc. strives to deepen relationships with customers. The Company also operates BloomNet®, an international floral and gift industry service provider offering a broad range of products and services designed to help members grow their businesses profitably; Napco℠, a resource for floral gifts and seasonal décor; and DesignPac®, a manufacturer of gift baskets and towers. 1-800-FLOWERS.COM, Inc. was recognized among America’s Most Trustworthy Companies by Newsweek for 2024. 1-800-FLOWERS.COM, Inc. was also recognized as one of America’s Most Admired Workplaces for 2025 by Newsweek and was named to the Fortune 1000 list in 2022. Shares in 1-800-FLOWERS.COM, Inc. are traded on the NASDAQ Global Select Market, ticker symbol: FLWS. For more information, visit 1800flowersinc.com.

FLWS-COMP
FLWS-FN

View source version on businesswire.com: https://www.businesswire.com/news/home/20260819221041/en/

Investors Contact:

Andy Milevoj

[email protected]

Media:

[email protected]

Source: 1-800-FLOWERS.COM, Inc.

Release – DLH to Provide Mission-Critical Cyber Support for U.S. Navy

Posted on August 18, 2026August 18, 2026 by [email protected]

Research News and Market Data on DLHC

August 18, 2026

PDF Version

ATLANTA, Aug. 18, 2026 (GLOBE NEWSWIRE) — DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of digital transformation and cybersecurity, systems engineering and integration, and science research and development, today announced it has been awarded a multiple-award indefinite delivery/indefinite quantity (“MAC ID/IQ”) contract to provide technical services in support of cyberspace activities for the U.S. Navy. The Cyberspace Science, Research, Engineering and Technology Integration Unrestricted Multiple Award Contract is administered by Naval Information Warfare Center (“NIWC”) Pacific.

Through task orders to be competed under this contract, DLH will have the opportunity to support the architecture, engineering, functionality, interface, and interoperability of cyberspace systems, services, and capabilities at the tactical, operational, and strategic levels, including all enabling technologies. Services may include technology assessment, systems engineering, software and hardware development and prototyping, modeling and simulation, training support, and cybersecurity.

DLH is one of 29 prime awardees of the contract, which includes a base period of five years and one option period of two additional years. The contract has a total ceiling for all awardees of $400 million. Task orders are expected to be released under the contract, for which DLH expects to compete.

“DLH leverages speed, agility, world-class engineering services, and leading-edge technology, including artificial intelligence and machine learning, to deliver mission-critical cyber support,” said Billy Burnett, President of DLH’s Defense & Security business group. “This award expands the avenues available to our company to support Navy customers.”

About DLH

DLH (NASDAQ: DLHC) enhances technology, public health, and cyber security readiness missions through science, technology, cyber, and engineering solutions and services. Our experts solve some of the most complex and critical missions faced by federal customers, leveraging digital transformation, artificial intelligence, advanced analytics, cloud-based applications, telehealth systems, and more. With a world-class workforce dedicated to the idea that “Your Mission is Our Passion,” DLH brings a unique combination of government sector experience, proven methodology, and unwavering commitment to innovative solutions to improve the lives of millions. For more information, visit www.DLHcorp.com.

Contact Information:

Investor Relations
[email protected]

Media
[email protected]

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or DLH`s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that the Company or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward-looking statements that involve risks and uncertainties which could cause actual events or DLH’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements in this release include, among others, statements regarding the anticipated use of proceeds. These statements reflect our belief and assumptions as to future events that may not prove to be accurate. Our actual results may differ materially from such forward-looking statements due to a variety of factors, including: the failure to achieve the anticipated benefits of any future acquisition (including anticipated future financial operating performance and results); the inability to retain employees and customers; contract awards in connection with re-competes for present business and/or competition for new business; our ability to manage our debt obligations; compliance with bank financial and other covenants; changes in client budgetary priorities; government contract procurement (such as bid and award protests, small business set asides, loss of work due to organizational conflicts of interest, etc.) and termination risks; significant delays or reductions in appropriations for our programs and broader changes in U.S. government funding and spending patterns; legislation that amends or changes discretionary spending levels or budget priorities; legal, regulatory, and political changes from the federal government that could result in economic uncertainty; the impact of inflation and higher interest rates; and other risks described in our SEC filings. For a discussion of such risks and uncertainties which could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” in the Company’s periodic reports filed with the SEC, including our Annual Report on Form 10-K for the fiscal year ended September 30, 2025, as well as interim quarterly filings thereafter. The forward-looking statements contained herein are not historical facts, but rather are based on current expectations, estimates, assumptions and projections about our industry and business.

Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company does not assume any responsibility for updating forward-looking statements.

Release – The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon

Posted on August 18, 2026August 18, 2026 by [email protected]

Research News and Market Data on NNVC

Shelton, Connecticut – Tuesday, August 18, 2026.

NanoViricides, Inc. (NYSE American: NNVC) (the “Company”), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus and other Ebola viruses is expected to begin soon in the Democratic Republic of Congo (“DRC”).

Professor Patrick Katoto has been appointed as the principal investigator to lead this clinical trial. Dr. Katoto 1 is Co-Director and Co-Founder of the Centre for Tropical Diseases and Global Health (“CTDGH”), and Associate Professor of Medicine, Epidemiology and Global Health at the Catholic University of Bukavu, Bukavu, DRC. He has more than ten years of working experience as a clinician, academic, and advisor for multiple public and private health agencies. He works on various projects of global health concern to produce evidence to inform decision-making to address Ebola, COVID-19, HIV, tuberculosis, vaccine-preventable diseases, non-communicable diseases, as well as air pollution in resource-limited settings. He has published over fifty papers in renowned journals such as Lancet and JACC. He has co-authored a paper entitled “How to prepare for the next inevitable Ebola outbreak: lessons from West Africa [2014-2016]” in 2024 in Nature Medicine 2.

Patrick is a Fogarty Fellow (HIV-comorbidity research training program in Low and Medium Income Countries (“LMIC”s), a Fellow of the Central & West Africa Implementation Science Alliance for the establishment of a network in implementation research (known as “CAWISA”, in collaboration with the University of Maryland Baltimore, Institute of Human Virology Nigeria, Yale University and other organizations) to accelerate the scaling up of novel diagnostic tools and clinical guidelines to improve children’s health, a fellow of the Pan-African Scientific Research Council and a member of the Institute for Health Metrics’ Global Burden of Diseases project (University of Washington).

Under the leadership of Professor Katoto, NanoViricides, as the drug sponsor of NV-387 Oral Gummies, has received regulatory approval to begin a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus and other Ebola viruses, from the local regulatory agency ACOREP in the Democratic Republic of Congo (DRC).

Professor Katoto and his team have already actively started the preparatory work including staff training, to accelerate time to first patient dosing, even without waiting for the regulatory approval. This has a given a head start to our efforts.

Additionally, the drug product for the clinical trial is already available in DRC, because of the impending Phase II clinical trial of NV-387 Oral Gummies as a Treatment for Mpox.

Therefore, it is anticipated that the first Ebola patient dosing with NV-387 oral gummies under this clinical trial can be expected to occur within a few weeks, barring impediments caused by the very ebola disease outbreak that the trial is designed to respond to.

“We now eagerly await the first dosing of Ebola patients with our NV-387 Oral Gummies drug product that is already in place in DRC,” said Anil R. Diwan, PhD, President of the Company, adding, “We, our colleagues, and our partners are hoping that this orally available, unique and revolutionary broad-spectrum antiviral drug succeeds in combatting the Bundibugyo virus for which there is no known treatment or vaccine.”

1 https://ctdgh.org/researchers/prof-dr-katoto-pdm , also see-https://cawisa-afr.org/team-member/patrick-dmc-katoto/

2 http://europepmc.org/abstract/med/39420216
As the Ebola outbreak continues to expand, several limitations on travel are being instated. There are also limitations on availability of resources such as PPE and diagnostic kits, which are compounded by the travel and other restrictions. These on-ground situations have caused delays in our efforts, and we anticipate such delays to continue due to the tenuous outbreak situation.

The current Ebola Virus Disease (EVD) caused by the Bundibogyo ebolavirus (BDBV) is now the largest ever ebola outbreak, as well as the fastest growing ebola outbreak in DRC. As of August 14, 2026, there have been 4945 confirmed cases, and 2325 deaths, with 101 new cases being confirmed in the previous 24 hrs 3. In comparison, as of August 6, 2026, there were reported 4,141 confirmed cases and 1,889 confirmed deaths due to this virus. Only 829 confirmed cases were then reported to have recovered from the disease. The crude fatality rate (crude CFR) is 46%, according to the WHO 4.

This is an increase of 20% in cases as well as deaths over the prior week. At this rate, the current deadly outbreak is on track to exceed the worst ever ebola zaire outbreak in West Africa in 2014-2016. In that outbreak, 28,616 cases and 11,310 deaths were recorded across Guinea, Liberia and Sierra Leone, according to the World Health Organization (ibid, #3).

An oral drug to treat patients, to prevent contacts from contracting the disease, and to keep healthcare workers safe, is sorely needed to combat this outbreak. There is a tremendous urgency to validate a drug that works against this ebolavirus in short and decisive clinical trials for minimizing further spread by treating patients and for saving lives. Om Sai CRO, in consultation with renowned scientists in DRC, has designed the Phase II clinical trial with this particular objective.

In contrast, the “PARTNERS” clinical trial (see below) will require over 1,000 patients to be treated and may not yield results for at least more than a year. A similar large collaborative clinical trial effort in the West Africa 2014-2016 outbreak resulted in US FDA approval of two antibody drugs only specifically for EBOV Zaire, which are not deemed to be useful in the current outbreak without further clinical trials.

NV-387 is the only orally active agent under consideration for clinical trial as a treatment of Ebola to the best of our knowledge. In an epidemic scenario in resource limited settings such as in DRC, we believe an oral drug is a highly advantageous feature.

An oral drug called obeldesivir, which is related to the known drug remdesivir that previously failed in clinical trials against Ebola Zaire, is being tried in a clinical trial, but only as a preventative measure, and not as a treatment of active infection.

NanoViricides has retained Om Sai Clinical Research Private Limited, India, (Om Sai CRO) as the CRO for this Phase II clinical trial for Ebola in DRC. Om Sai CRO has been instrumental in putting together the team with Prof. Katoto and other renowned experts and with support from the University ofukavu and in the Ebola-affected region to lead and execute the clinical trial of NV-387 Oral Gummies as a Treatment for Ebola viruses in DRC.

This Ebola outbreak continues to increase in spread and is now present in at least six provinces in

3 https://www.cbc.ca/news/world/drc-ebola-outbreak-deadliest-in-history-9.7309296

4 https://www.who.int/emergencies/alert-and-response . The crude CFR is estimated as number of

deaths (1,889) divided by number of reported confirmed cases (4,141) since May 16, the declaration of the epidemic. Most of the remaining 1,423 cases are likely to be continuing as disease-stricken. The crude CFR does not take into account the delay period between case confirmation to case fatality (i.e. the disease duration), and results in an underestimate of the case fatality rate while the epidemic is still increasing, as is the case at present in DRC.

The largest ever Ebola outbreak was the West Africa Ebolavirus (Zaire) outbreak, in 2013-2016, that killed more than 11,000 people out of at least 28,000 cases. The current outbreak, caused by a different, rare Bundibugyo strain of the ebolavirus, has already surpassed that outbreak in becoming the fastest growing Ebola outbreak to date, according to the WHO.

DRC and threatening South Sudan 5. More concerning is the fact that over 80% of new cases are outside of known contact lists, leading to the projection that the extent of the outbreak is at least two times or more larger than the reported confirmed cases 6. Additionally, Ebola is now found to have spread into displacement camps that host over 4.4 million displaced persons due to internal warfare, adding another high risk population pool with poor drinking water, sanitation and medical resources to further fuel this outbreak, according to the UN New Service 7.

Treatments under consideration except for NV-387 which is orally available, require infusions. Infusions are difficult to implement and also are not scalable in a large outbreak scenario such as this Ebola virus outbreak if it continues to grow, as has been widely expected.

A clinical trial, called the “PARTNERS” clinical trial, evaluating Remdesivir infusion, an antibody cocktail MBP134 infusion, and MBP134 infusion plus Remdesivir infusion, has started according to WHO with first patient having received infusion of the antibody cocktail on July 2, 2026 8.

“Although this antiviral (Remdesivir) proved to be ineffective at targeting the Zaire Ebolavirus, there remains hope that it could have some benefit against the Bundibugyo virus, particularly if used in combination with MBP-134,” according to an article in Forbes explaining the “PARTNERS” clinical trial

by the WHO organized collaboration 9. The article also notes that MBP134 contains two separate

antibodies designed to, taken together, recognize multiple Ebola species.

Antibodies are highly specific to a particular strain of the virus and usually are not very effective against variants of the same virus that arise in the field. Viruses also escape antibodies readily by mutations in the field.

The Company notes that NV-387 was previously found to be superior to Remdesivir in a lethal animal model of a viral disease. The Company believes this superiority of NV-387 is reasonably expected to extend to the current novel Bundibugyo ebolavirus strain.

There is no approved Treatment or Vaccine for the new variant of the Bundibugyo Ebolavirus (BDBV) that is causing the current rapidly expanding outbreak of the Ebolavirus Disease (EVD) in DRC. The rare Bundibugyo strain of Ebola virus causing the current outbreak appears to be its new variant, likely freshly introduced from some animal source 10, such as fruit bats.

A new clinical trial of an Oxford University designed Bundibugyo-specific vaccine has also started in DRC, in addition to the treatment trials of antibody and remdesivir infusions (ibid, #8). Further, Ervebo, a vaccine approved for Ebolavirus Zaire, may also enter clinical trials for the protection of uninfected persons from the distinctly different Bundibugyo ebolavirus due to the enormity of the

5 https://www.aljazeera.com/news/2026/7/20/ebola-death-toll-in-drc-surges-to-at-least-930-as-outbreak-gathers-pace

https://www.aljazeera.com/news/2026/7/16/ebola-spreading-more-quickly-in-drc-while-uganda-is-close-to-being-virus-free

6 https://www.msn.com/en-us/health/other/congos-ebola-outbreak-spreads-to-two-more-provinces/ar-AA27NkjT

7 https://www.msn.com/en-xl/africa/top-stories/ebola-virus-reaches-displacement-camps-in-dr-congo/ar-AA29A5ts?ocid=BingNewsSerp

8 https://www.reuters.com/business/healthcare-pharmaceuticals/trial-bundibugyo-ebola-treatment-starts-drc-who-says-2026-07-02/

9 https://www.forbes.com/sites/omerawan/2026/07/07/new-clinical-trials-offer-hope-in-the-fight-against-ebola-in-the-democratic-republic-of-congo/

10 https://virological.org/t/initial-genomes-from-may-2026-bundibugyo-virus-disease-outbreak-in-the-democratic-republic-of-the-congo-and-uganda/1032

emergency posed by the current outbreak despite reservations regarding a potentially imperfect vaccine 11. Om Sai is the CRO leading the Company’s Phase II clinical trial of NV-387 Oral Gummies as a

Treatment for Mpox in DRC, and the same CRO is also leading the newly approved Ebola clinical trial.

Sufficient quantity of NV-387 Oral Gummies Drug Product for starting the clinical trial against Ebola is already available in DRC. This drug product was shipped to DRC for the ensuing Phase II clinical trial of NV-387 for the Treatment of Mpox and also to support the Phase II clinical trial for the Treatment of Ebola only upon approval by the regulatory agency, which has now been approved.

“We believe NV-387 could be revolutionary in this fight against Ebola, if it is found to be effective,” said Anil R. Diwan, PhD, adding, “It is an oral drug, in contrast to others that are infusions. Thus evaluating if NV-387 treatment works is of paramount importance to combat this and future Ebola and Marburg outbreaks.”

NV-387 is a broad-spectrum antiviral that mimics the host-side features that the virus requires, and is likely to be effective against Ebola viruses because they use the same host-side feature mimicked by NV-387.

It is highly unlikely that viruses can escape NV-387, because this drug mimics the features on host cells that the viruses continue to require even as they mutate or evolve in the field.

Additionally, NV-387 Oral Gummies is a drug product readily delivered orally. It does not even require swallowing effort or water, because it dissolves in the mouth by itself, simplifying delivery for even sick individuals with swallowing difficulties.

This oral delivery is an important feature that puts NV-387, a broad-spectrum antiviral, as being superior to the other approaches.

“Only safe and effective broad-spectrum antiviral drugs like NV-387 that can effectively tackle most viral infections will enable the world to combat viruses and defend the global population in the war against known and unknown nanoscopic enemies that are viruses,” commented Dr. Diwan, adding, “Today, NV-387 is the only drug in clinical development with such broad-spectrum potential that promises to combat diverse epidemics like Mpox and Ebola, to the best of our knowledge.”

While there is currently minimal risk of Ebola in the USA, the CDC’s mathematical models suggested this Central African outbreak could grow to 10,000 to 20,000 cases and 2,000 to 4,000 deaths within just three months, rivaling the largest outbreak to date in 2014-2016 12. Unfortunately, the outbreak appears to be even more aggressive than the CDC model, with over 2,000 deaths in less than three months, over 4,000 confirmed cases, and over 10,000 estimated total cases 13.

The outbreak which was declared a Public Health Emergency of International Concern (“PHEIC”) by the WHO on May 17, 2026, continues to rapidly expand, outpacing containment efforts. The outbreak arose in a high traffic region bordering the Democratic Republic of Congo (DRC), with travel contacts to Uganda, and South Sudan and with 11 more nations in Africa at risk 14.

NV-387 is a broad-spectrum antiviral that mimics the host-side feature called heparan sulfate

11 https://www.msn.com/en-us/health/general/ebola-cases-top-4-000-in-drc-as-who-urges-ervebo-vaccine-trial/ar-AA29CX9f?ocid=BingNewsSerp .

12 https://www.cdc.gov/media/releases/2026/update-on-ebola-outbreak-in-the-democratic-republic-of-the-congo-and-uganda-6-5-2026.html

13 The WHO and Africa CDC have estimated that the confirmed case number substantially under-represents actual case numbers which could be at least double or even more than confirmed cases. See #5.

14 https://www.forbes.com/sites/maryroeloffs/2026/05/25/african-health-officials-on-ebola-this-is-too-much-live-updates/

proteoglycan (HSPG) that over 90-95% of human pathogenic viruses require for infecting cells. No matter how much the virus changes in the field, it continues to use HSPG, and therefore it cannot escape the drug NV-387. In contrast, Remdesivir is a small molecule inhibitor of the viral RDRP enzyme needed for making copies of the viral genome, and the virus can possibly escape by small number of mutations.

All Ebola viruses utilize HSPG as the attachment receptor prior to gaining entry into the cell. Thereafter, followed by entry into the cell inside endosomes, the ebolavirus surface glycoprotein is substantially degraded, opening up its site for binding to its cognate receptor called NPC1, thereby entering into the cytoplasm where the next steps in its replication begin.

Thus there is a strong rationale that NV-387 could be highly effective against Ebola virus infections, not just Bundibugyo, but also the Sudan and other viruses for which there are no treatments.

NV-387 is available as an oral medication that has excellent stability at room temperature, enabling ease of transport, distribution, and delivery to patient. NV-387 oral gummies dissolve naturally in the mouth and do not require tablet swallowing, which is difficult for children, seniors, and also patients with sore throat.

All previous anti-Ebola efforts have been focused on vaccines and antibodies 15. This has led to approval of therapies that are specific to the Ebolavirus Zaire strain only, albeit with limited effectiveness. This leaves out all other filoviruses of consequence: Sudan, Marburg, and the more rare Bundibugyo with no treatment or vaccine.

In contrast, if NV-387, as a broad-spectrum antiviral, is found to be effective against the Bundibugyo virus, it will likely be effective against all ebolaviruses and possibly all filoviruses; that would be a game changer for pandemic preparedness.

The case fatality rate of ebolaviruses has generally been approximately 50% in recent outbreaks, with improvements in care, including hydration therapy, corticosteroids, and other usual symptomatic treatments. Ebola viruses spread via bodily fluid secretions including fomites/sputum, as well as semen/ genital secretions. Ebola virus can remain in survivors even as many as 965 days after the disease without symptoms, and can transmit through bodily secretions, suggesting possible latency. Many recent outbreaks have been ignited as a result of such reawakened-transmitted virus from a survivor. Sexual transmission was documented even as late as 482 days after disease. This persistence and possible latency of ebolavirus in immune-privileged organs (e.g. brain, eyes, gonads, where antibodies are not operative) makes it a uniquely serious threat for global transmission and sustained outbreaks.

At present, BDBV has been consistently demonstrating crude CFR exceeding 46% in DRC. Therefore, BDBV is of great concern as a potential pandemic disease. However, it is believed that ebolaviruses do not transmit via respiratory droplets or aerosols and rather require extensive contact with bodily fluids of an infected person. In addition, within DRC and internationally, certain protective quarantine measures for travel from the outbreak areas have been implemented.

Therefore, currently there is no apparent threat of a global pandemic.

An irony is that because of the high case fatality rate (CFR) approaching 50%, the spread of ebolaviruses remains rather limited. If a variant emerges with a reduced CFR, say in the range of 5-15%, the potential threat of global pandemic from such an outbreak would increase substantially.

With ever-increasing global travel, local outbreaks such as ebola can quickly travel far and wide potentially causing global pandemics, as was the case with COVID-19, if not caught in time. It is not feasible to produce a new vaccine and a new set of antibody drugs to combat every possible virus. Even if vaccines and antibodies are produced, the virus would escape by generating variants, as the world has witnessed during the COVID-19 pandemic.

The US Government is active in ensuring that suspected or confirmed ebolavirus cases do not

15 Substantial work was also performed to develop small chemical potentially broad-spectrum agents. Remdesivir was the only small chemical that entered the PALM clinical trials ca. 2018-2019 but failed to show effectiveness. Small chemicals are readily escaped by viruses often with just single mutations.

enter the general population in the USA. To this end, travel from DRC has been restricted, with pre-travel quarantine requirements imposed, and suspect travelers are directed to screening at specific airports and may be further quarantined.

Travelers going to and from Central Africa need to constantly check travel restrictions as well as travel limitations in light of these changing outbreak conditions.

ABOUT NANOVIRICIDES

NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these

forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.

Contact: NanoViricides, Inc.
[email protected]
Public Relations Contact: [email protected]
Source: NanoViricides, Inc.

Release – Resolution Secures White House FAST-41 Transparency Coverage for Golden Gate Tungsten-Gold Target

Posted on August 17, 2026August 17, 2026 by [email protected]

Research News and Market Data on RLMLF

July 17, 2026

PERMITTING COUNCIL SUPPORT EXPECTED TO ACCELERATE AGGRESSIVE EXPLORATION AND DEVELOPMENT PROGRAM ACROSS ENTIRE GOLDEN GATE TARGET AS RESOLUTION CONTINUES TO DEVELOP ITS INTEGRATED IDAHO ANTIMONY-TUNGSTEN-GOLD CRITICAL METALS PLATFORM

July 17, 2026 (Source) — HIGHLIGHTS

This is the second FAST-41 status granted to Resolution Minerals, demonstrating the high calibre of the Golden Gate asset and its strategic value as a potential source of U.S. domestic tungsten supply, and highlights the level of engagement RML has with the U.S. Government and the Permitting Council, and the attention Resolution’s projects are receiving from the highest levels of the current Administration.
FAST-41 is a special permitting framework being utilised by the Trump Administration to accelerate permitting and the development of critical U.S. infrastructure projects and to provide solutions for U.S. national security.
RML’s Golden Gate Project was added to the FAST-41 Transparency Dashboard in response to President Trump’s Executive Order on Immediate Measures to Increase American Mineral Production¹, to reduce reliance on foreign adversaries for the supply of critical minerals, especially during times of war.
RML has been working closely with key Federal agencies and Administration leadership, including the Permitting Council, which has reviewed RML’s U.S. assets and has recognised their strategic importance to addressing the United States’ critical metals supply deficit and lack of domestic production.
With RML’s Antimony Ridge Project receiving FAST-41 Transparency status in April 2026, both of the Company’s primary development targets at the Horse Heaven Project, Antimony Ridge and Golden Gate, have been prioritised by the U.S. Government for streamlined permitting.
The Golden Gate and Antimony Ridge targets are within RML’s 15,000-acre Horse Heaven Tungsten-Antimony-Gold Project located in Idaho, USA, directly adjacent to Perpetua Resources’ recently permitted ~A$3.5 billion Stibnite Gold Project.
A Plan of Operations for Golden Gate has been submitted to, and accepted by, the US Forest Service for an exploration and development program that will include construction of new roads between Golden Gate North and Golden Gate South and allow up to 340 drill holes and 2,000 feet of trenching.
The Golden Gate Project includes the past-producing Golden Gate Tungsten Mine, which operated intermittently between the period from approximately 1952 to 1980, with reported tungsten production grades ranging between 1.5% and 2.0%.
The combination of Golden Gate and Antimony Ridge positions Resolution to pursue an integrated critical metals development pathway spanning exploration, metallurgy, and potential downstream processing in a tier-one U.S. jurisdiction.
FAST-41 status is expected to fast-track permitting, enhance investor visibility and support engagement with potential strategic partners and funding sources aligned with the U.S. critical minerals policy.
FAST-41 status bodes extremely well for the Company’s upcoming NASDAQ listing.

Resolution Minerals Ltd (ASX: RML; OTCQB: RLMLF) (“Resolution” or the “Company”) is pleased to announce that its Golden Gate Project in Idaho, USA has been selected for inclusion in the U.S. Federal FAST-41 Permitting Transparency Program.

FAST-41 designation is expected to accelerate permitting timelines through enhanced inter-agency coordination, transparent milestone tracking and dedicated federal oversight. The Program provides Resolution with a clear pathway to advance its proposed bulk sampling and drilling activities at Antimony Ridge, a high-grade, past producing antimony project, located within the Company’s 100% owned Horse Heaven Project.

Importantly, FAST-41 selection supports Resolution’s broader strategy to develop a U.S.-focused critical mineral platform. Golden Gate is one of several advancing components within Horse Heaven Project, which also includes:

A recently acquired processing mill and infrastructure known as the Johnson Creek Tungsten Mill.
Historical tungsten stockpiles located adjacent to the Golden Gate Tungsten Mine portal and at the Johnson Creek Mill with potential near-term development optionality.
A fully funded, ongoing Phase 2 drilling program at Golden Gate, comprising up to 45 holes targeting resource definition.

Together, these assets position Resolution to pursue an integrated development pathway spanning exploration, metallurgy and potential downstream processing of antimony, tungsten, and gold in a tier-one U.S. jurisdiction.

Golden Gate is located immediately adjacent to Perpetua Resources’ Stibnite Gold Project, highlighting the region’s growing importance as a strategic hub for U.S. critical minerals. With the United States seeking to secure domestic supply of key metals such as antimony, Resolution is well placed to contribute to supply chain resilience while advancing multiple near-term development catalysts.

The inclusion of Golden Gate in the FAST-41 program follows closely on the designation of RML’s Antimony Ridge Project as a FAST-41 project. It is the intention of the US Forest Service to permit both the Antimony Ridge Plan of Operation and the Golden Gate Plan of Operation under one NEPA process, helping to streamline ongoing permitting at both projects.

Craig Lindsay, Resolution’s CEO – US Operations, commented:

“We are very pleased that Golden Gate has been selected for FAST-41 Transparency Coverage. We now have two separate development targets within the Horse Heaven Project under the FAST-41 program. Interestingly, I am not aware of any other critical metals company with two FAST-41 projects, which I believe is a mark of the potential importance of Horse Heaven in the US achieving its goal of developing domestic supplies of both antimony and tungsten.

Golden Gate represents a key piece of Resolution’s broader strategy to develop a U.S.-based critical minerals platform. With exploration, processing infrastructure and multiple development pathways now coming together at Horse Heaven, we believe the Company is uniquely positioned to capitalise on strong demand for antimony, tungsten and gold.”

FAST-41 Projects and the Permitting Council

The Washington, DC-based Permitting Council was established by Congress in 2015 under Title 41 of the Fixing America’s Surface Transportation Act (FAST-41) to improve the efficiency, transparency and accountability of the federal permitting process.

The Council coordinates environmental reviews and authorisations across multiple federal agencies, acting as a central project manager across for qualifying projects. FAST-41 projects benefit from structured inter-agency coordination, defined permitting timelines and public tracking via the Federal Permitting Dashboard.

The Permitting Council is comprised of the Executive Director (Chair), and 15 other members, including the Deputy Secretary (or equivalent) from 13 Federal agencies, the Chair of the Council on Environmental Quality (CEQ), and the Director of the Office of Management and Budget (OMB). The Office of the Executive Director (OED) executes on the actions of the Council, and Permitting Council statutory authorities, programs, and initiatives. The Office of the Executive Director coordinates federal environmental reviews and authorisations for projects that qualify for FAST-41 coverage, which are in turn entitled to public permitting timetables and transparent, collaborative management of those timetables on the Federal Permitting Dashboard.

More information on the Permitting Council and FAST-41 can be found at www.permitting.gov.

Next Steps

Resolution will work closely with its primary permitting authority, the US. Forest Service, to advance the Golden Gate Plan of Operations through the FAST-41 process.

Following approval, the Company intends to commence a significant drill campaign intended to both increase the drill coverage of the Golden Gate North and Golden Gate South targets and confirm whether the gold and tungsten mineralization is linked geologically (the area between North and South have never been drilled, but RML has developed a geologic model that suggests the potential for both targets to be one large contiguous body of mineralisation).

On a parallel basis, RML is continuing to implement its ongoing 13,700 metre (45,000 foot) drill program at Golden Gate, with 22 holes currently completed and initial results for the first several holes expected by the end of July.

Authorised for release by the Board of Resolution Minerals Ltd.

For further information, please contact:

Ari Zaetz
Executive Director
Resolution Minerals Ltd
M: +61 493 254 526
[email protected]

Jane Morgan
Investor Relations
Jane Morgan Management
M: +61 405 555 618
[email protected]

Forward Looking Statements

This announcement may contain forward-looking statements. These statements relate to the Company’s expectations, beliefs, intentions or strategies regarding the future. These statements can be identified by the use of words like “anticipate”, “believe”, “intend”, “estimate”, “expect”, “may”, “plan”, “project”, “will”, “should”, “seek” and similar words or expressions containing same. These forward-looking statements reflect the Company’s views and assumptions with respect to future events as of the date of this release and are subject to a variety of unpredictable risks, uncertainties, and other unknowns. Actual and future results and trends could differ materially from those set forth in such statements due to various factors, many of which are beyond our ability to control or predict. These include, but are not limited to, risks or uncertainties associated with the acquisition and divestment of projects, joint venture and other contractual risks, metal prices, exploration, development and operating risks, competition, production risks, sovereign risks, regulatory risks including environmental regulation and liability and potential title disputes, availability and terms of capital and general economic and business conditions.

Given these uncertainties, no one should place undue reliance on any forward-looking statements attributable to the Company, or any of its affiliates or persons acting on its behalf. Subject to any continuing obligations under applicable law, the Company disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements in this announcement to reflect any change in expectations in relation to any forward-looking statements or any change in events, conditions or circumstances on which any such statement is based.

References:

https://www.whitehouse.gov/presidential-actions/2025/03/immediate-measures-to-increase-american-mineral-production

https://www.mining.com/tungsten-crunch-can-be-fixed-before-prices-spike-further-bmo

https://www.nationalacademies.org/read/12028/chapter/10

D. W. Kalmbach et al 2021: NI 43-101 TECHNICAL REPORT ON THE HORSE HEAVEN GOLD PROJECT VALLEY COUNTY